Clinical Trials Browser

Smoldering Multiple Myeloma, Lymphoma, Waldenstrom Macroglobulinemia, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT06971848 2026-03-30

ETCABIO

Phase NA Not yet recruiting

70 enrolled

GastrointestinalLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellThoracic

Immunoglobulin Light-chain Amyloidosis, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Carcinoma, Bronchogenic, Heart Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Follicular, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT04680468 2026-03-23

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

Phase 2 Active not recruiting

41 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT07354555 2026-03-20

MMExFFPE

Not yet recruiting

15 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02952508 2026-03-18

CLOVER-WaM

Phase 2 Active not recruiting

120 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT02886065 2026-03-13

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Phase 1 Active not recruiting

19 enrolled

Plasma cell

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

33 enrolled 11 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06066359 2026-03-11

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Phase 1/2 Recruiting

44 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT03633955 2026-03-05

REALIZE

Phase 1 Recruiting

60 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT04328662 2026-03-04

A Study of Ninlaro in Real World Clinical Practice in China

Completed

482 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07297160 2026-03-04

CALySSEY

Phase 1 Not yet recruiting

88 enrolled

GenitourinaryLymphoidOther hematologic neoplasmPlasma cellSarcoma

Kidney Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Phase 4 Not yet recruiting

80 enrolled

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

NCT05745285 2026-02-20

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

Phase NA Recruiting

400 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT03480360 2026-02-19

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Phase 3 Active not recruiting

21 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Lymphoma, Lymphoma, Non-Hodgkin, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell, Primary Myelofibrosis

NCT07410403 2026-02-13

AI

Enrolling by invitation

10 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04155749 2026-02-11

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Phase 1 Active not recruiting

40 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04751877 2026-02-10

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

Phase 3 Active not recruiting

270 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

125 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07390071 2026-02-05

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Phase NA Recruiting

40 enrolled

LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Neoplasms, Plasma Cell

NCT01208662 2026-01-22

DFCI 10-106

Phase 3 Active not recruiting

729 enrolled 29 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01269593 2026-01-15

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

Phase EARLY_PHASE1 Active not recruiting

63 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT05063591 2026-01-15

BRUOG-407

Phase NA Completed

18 enrolled 8 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT05625971 2026-01-07

NIRVANA

Completed

36 enrolled

Plasma cell

Neoplasm, Residual, Neoplasms, Plasma Cell

NCT01208766 2026-01-06

HO95

Phase 3 Completed

1,503 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03702725 2026-01-06

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1 Completed

14 enrolled 15 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Phase 2 Completed

39 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT07319897 2026-01-06

A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.

Phase 2/3 Not yet recruiting

300 enrolled

Plasma cell

Disease, Multiple Myeloma, Neoplasms, Plasma Cell

NCT04952766 2025-12-23

EREVA

Phase 4 Completed

196 enrolled

Other hematologic neoplasmPlasma cell

Acquired Immunodeficiency Syndrome, Diabetes Mellitus, Type 2, Hypergammaglobulinemia, Multiple Sclerosis, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT00466674 2025-12-19

IFM 2005-03

Phase 2 Completed

13 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT05055063 2025-12-18

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Phase 1 Recruiting

30 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT04268199 2025-12-15

EASE

Phase 2 Recruiting

100 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

Phase 1 Completed

31 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06518551 2025-12-11

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Phase 1/2 Recruiting

49 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05065866 2025-12-04

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Phase 1 Completed

14 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT06947083 2025-12-03

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Phase 2 Recruiting

39 enrolled

Plasma cell

Neoplasms, Plasma Cell

Clinical Trials

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pre-malignant States to Hematologic Malignancies in Firefighters

REMAKE

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

Genome Expression in Lymphoma, Leukemia and Multiple Myeloma

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

IFM2005-02

IFM/DFCI2009

Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

ETCABIO

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

MMExFFPE

CLOVER-WaM

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

REALIZE

A Study of Ninlaro in Real World Clinical Practice in China

CALySSEY

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

AI

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

DFCI 10-106

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

BRUOG-407

NIRVANA

HO95

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.

EREVA

IFM 2005-03

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

EASE

FT576 in Subjects With Multiple Myeloma

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma